-
Vetr Top Raters Downgrade Zafgen To 1.5-Star Stock
Tuesday, February 16, 2016 - 4:36pm | 147Zafgen Inc (NASDAQ: ZFGN) investors may be having a difficult time in evaluating the stock's prospects following a more than 80 percent drop over the past year. Despite a more than 10 percent gain since the start of 2016, Vetr top raters downgraded Zafgen's stock rating to 1.5-stars. In fact,...
-
Kerrisdale Short Zafgen, Says Beloranib Has 'No Reasonable Chance' Of FDA Approval And Recent Bullishness Is 'Misplaced'
Monday, January 25, 2016 - 10:36am | 551Zafgen Inc (NASDAQ: ZFGN) shares are up 41 percent in the last five trading days amid positive data for beloranib's ability to treat weight loss in patients with Prader-Willi syndrome. In a new report Monday morning, hedge fund Kerrisdale Capital said it is short the stock with a $3 price...
-
Why Zafgen Is Trading Higher By 40%
Wednesday, January 20, 2016 - 9:45am | 320Shares of Zafgen Inc (NASDAQ: ZFGN), a biopharmaceutical company that develops therapies for patients affected by obesity and complex metabolic disorders, were trading higher by nearly 40 percent at $7.80 early Wednesday morning. Zafgen announced after Tuesday's market positive efficacy...